Dynavax Technologies Corp
Company Profile
Business description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Contact
2100 Powell Street
Suite 720
EmeryvilleCA94608
USAT: +1 510 848-5100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
405
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,723.50 | 17.90 | -0.20% |
CAC 40 | 7,589.66 | 36.21 | 0.48% |
DAX 40 | 23,350.55 | 293.17 | 1.27% |
Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
FTSE 100 | 8,774.65 | 17.15 | -0.20% |
HKSE | 23,530.48 | 292.74 | 1.26% |
NASDAQ | 19,447.41 | 98.86 | -0.51% |
Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
S&P 500 | 5,967.84 | 13.03 | -0.22% |
S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
SSE Composite Index | 3,359.90 | 2.21 | -0.07% |